These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 29981849)

  • 1. Favorable Outcome of Post-Transplantation Cyclophosphamide Haploidentical Peripheral Blood Stem Cell Transplantation with Targeted Busulfan-Based Myeloablative Conditioning Using Intensive Pharmacokinetic Monitoring in Pediatric Patients.
    Hong KT; Kang HJ; Choi JY; Hong CR; Cheon JE; Park JD; Park KD; Song SH; Yu KS; Jang IJ; Shin HY
    Biol Blood Marrow Transplant; 2018 Nov; 24(11):2239-2244. PubMed ID: 29981849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells.
    Cieri N; Greco R; Crucitti L; Morelli M; Giglio F; Levati G; Assanelli A; Carrabba MG; Bellio L; Milani R; Lorentino F; Stanghellini MT; De Freitas T; Marktel S; Bernardi M; Corti C; Vago L; Bonini C; Ciceri F; Peccatori J
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1506-14. PubMed ID: 26001696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-Transplantation Cyclophosphamide-Based Haploidentical versus Matched Unrelated Donor Peripheral Blood Hematopoietic Stem Cell Transplantation Using Myeloablative Targeted Busulfan-Based Conditioning for Pediatric Acute Leukemia.
    Hong KT; Park HJ; Kim BK; An HY; Choi JY; Kang HJ
    Transplant Cell Ther; 2022 Apr; 28(4):195.e1-195.e7. PubMed ID: 35021131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Favorable outcome of hematopoietic stem cell transplantation using a targeted once-daily intravenous busulfan-fludarabine-etoposide regimen in pediatric and infant acute lymphoblastic leukemia patients.
    Lee JW; Kang HJ; Kim S; Lee SH; Yu KS; Kim NH; Jang MK; Kim H; Song SH; Park JD; Park KD; Shin HY; Jang IJ; Ahn HS
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):190-5. PubMed ID: 25255163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced-dose post-transplant cyclophosphamide plus low-dose post-transplant anti-thymocyte globulin as graft-versus-host disease prophylaxis with fludarabine-busulfan-cytarabine conditioning in haploidentical peripheral blood stem cell transplantation: A multicentre, randomized controlled clinical trial.
    Zhang W; Gui R; Zu Y; Zhang B; Li Z; Zhang Y; Wang X; Guo S; Zhan X; Fu Y; Song Y; Zhou J
    Br J Haematol; 2023 Jan; 200(2):210-221. PubMed ID: 36200642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haplo-Cord transplantation compared to haploidentical transplantation with post-transplant cyclophosphamide in patients with AML.
    Kwon M; Bautista G; Balsalobre P; Sánchez-Ortega I; Montesinos P; Bermúdez A; de Laiglesia A; Herrera P; Martin C; Humala K; Zabalza A; Torres M; Bento L; Corral LL; Heras I; Serrano D; Buño I; Anguita J; Regidor C; Duarte R; Cabrera R; Gayoso J; Diez-Martin JL
    Bone Marrow Transplant; 2017 Aug; 52(8):1138-1143. PubMed ID: 28346415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
    Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Busulfan-based myeloablative conditioning regimens for haploidentical transplantation in high-risk acute leukemias and myelodysplastic syndromes.
    Gayoso J; Balsalobre P; Kwon M; Herrera P; Bermúdez A; Sampol A; Jiménez S; López-Corral L; Serrano D; Piñana JL; Pascual MJ; Heras I; Bento L; Varela R; Humala K; Zabalza A; Laiglesia A; Bastos-Oreiro M; Pérez-Corral A; Martínez-Laperche C; Buño I; Díez-Martín JL;
    Eur J Haematol; 2018 Sep; 101(3):332-339. PubMed ID: 29846964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide after Busulfan-Containing Reduced-Intensity Conditioning.
    Sugita J; Kawashima N; Fujisaki T; Kakihana K; Ota S; Matsuo K; Miyamoto T; Akashi K; Taniguchi S; Harada M; Teshima T;
    Biol Blood Marrow Transplant; 2015 Sep; 21(9):1646-52. PubMed ID: 26093044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone marrow versus peripheral blood as a graft source for haploidentical donor transplantation in adults using post-transplant cyclophosphamide-A systematic review and meta-analysis.
    Yu X; Liu L; Xie Z; Dong C; Zhao L; Zhang J; Gu J; Zhu HH
    Crit Rev Oncol Hematol; 2019 Jan; 133():120-128. PubMed ID: 30661648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Children with Advanced Acute Leukemia with Fludarabine-, Busulfan-, and Melphalan-Based Conditioning.
    Jaiswal SR; Chakrabarti A; Chatterjee S; Bhargava S; Ray K; O'Donnell P; Chakrabarti S
    Biol Blood Marrow Transplant; 2016 Mar; 22(3):499-504. PubMed ID: 26612281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial.
    Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2012 Dec; 18(12):1859-66. PubMed ID: 22863841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience.
    Zaidman I; Rowe JM; Khalil A; Ben-Arush M; Elhasid R
    Biol Blood Marrow Transplant; 2016 Jun; 22(6):1043-1048. PubMed ID: 27016193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes after Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide: A Systematic Review and Meta-Analysis Comparing Myeloablative with Reduced-Intensity Conditioning Regimens and Bone Marrow with Peripheral Blood Stem Cell Grafts.
    Arcuri LJ; Hamerschlak N; Rocha V; Bonfim C; Kerbauy MN
    Transplant Cell Ther; 2021 Sep; 27(9):782.e1-782.e7. PubMed ID: 34146733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia.
    Yahng SA; Kim JH; Jeon YW; Yoon JH; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Kim HJ
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):119-29. PubMed ID: 25300871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility and Outcome of Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant High-Dose Cyclophosphamide for Children and Adolescents with Hematologic Malignancies: An AIEOP-GITMO Retrospective Multicenter Study.
    Berger M; Lanino E; Cesaro S; Zecca M; Vassallo E; Faraci M; De Bortoli M; Barat V; Prete A; Fagioli F
    Biol Blood Marrow Transplant; 2016 May; 22(5):902-9. PubMed ID: 26860636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Different Conditioning Regimens of Haploidentical Hematopoietic Stem Cell Transplant in Patients With Acute Myeloid Leukemia.
    Jiang Y; Fang X; Sui X; Liu X; Li Y; Wang X; Xu H; Zhang L; Wang X
    Exp Clin Transplant; 2018 Dec; 16(6):736-744. PubMed ID: 29790457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical outcome of allogeneic hematopoietic stem cell transplantation with FLAG sequential busulfan/cyclophosphamide conditioning regimen for refractory/relapsed acute myeloid leukemia].
    Liu W; Li Y; Qiu ZX; Yin Y; Sun YH; Xu WL; Wang Q; Liang ZY; Dong YJ; Wang LH; Cen QN; Wang MJ; Wang WS; Ou JP; Ren HY
    Zhonghua Nei Ke Za Zhi; 2018 Aug; 57(8):576-581. PubMed ID: 30060329
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
    Le Bourgeois A; Mohr C; Guillaume T; Delaunay J; Malard F; Loirat M; Peterlin P; Blin N; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Lode L; Bene MC; Chevallier P
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):934-9. PubMed ID: 23523970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-Risk Hematologic Malignancies.
    Klein OR; Buddenbaum J; Tucker N; Chen AR; Gamper CJ; Loeb D; Zambidis E; Llosa NJ; Huo JS; Robey N; Holuba MJ; Kasamon YL; McCurdy SR; Ambinder R; Bolaños-Meade J; Luznik L; Fuchs EJ; Jones RJ; Cooke KR; Symons HJ
    Biol Blood Marrow Transplant; 2017 Feb; 23(2):325-332. PubMed ID: 27888014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.